(Total Views: 417)
Posted On: 06/27/2019 5:50:55 AM
Post# of 153888
Yes , in combo we don’t have overlap period since really entire study is overlap ( but they don’t call that ). During entire study in combo patients taking HAART and Leronlimab .
In pivotal mono , study will be design with longer overlap , we were told it will be 4 weeks .
During last over 26 weeks they see that with longer overlap they have best efficacy with 525 mg it was 95% , better then with 700 ,
so they talking with FDA what will be in pivotal .
Many very important discoveries done in the last year , including the newest ,
CCR5 density test , what they call
“ Receptor Occupancy Test “
In pivotal mono , study will be design with longer overlap , we were told it will be 4 weeks .
During last over 26 weeks they see that with longer overlap they have best efficacy with 525 mg it was 95% , better then with 700 ,
so they talking with FDA what will be in pivotal .
Many very important discoveries done in the last year , including the newest ,
CCR5 density test , what they call
“ Receptor Occupancy Test “
(0)
(0)
